
Performant (PHLT) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
33.3M
Operating Income
150.0K
0.45%
Net Income
-81.0K
-0.24%
EPS (Diluted)
$0.00
Balance Sheet Metrics
Total Assets
105.4M
Total Liabilities
27.2M
Shareholders Equity
78.1M
Debt to Equity
0.35
Cash Flow Metrics
Operating Cash Flow
898.0K
Free Cash Flow
1.5M
Revenue & Profitability Trend
Performant Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 123.0M | 113.7M | 109.2M | 124.4M | 155.9M |
Cost of Goods Sold | - | - | - | - | 100.7M |
Gross Profit | - | - | - | - | 55.3M |
Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 35.5% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 100.4M | 90.4M | 85.3M | 87.4M | 100.7M |
Other Operating Expenses | 32.0M | 29.4M | 30.8M | 38.3M | 42.2M |
Total Operating Expenses | 132.5M | 119.9M | 116.1M | 125.7M | 142.9M |
Operating Income | -9.5M | -6.1M | -6.9M | -1.3M | 13.0M |
Operating Margin % | -7.7% | -5.4% | -6.3% | -1.1% | 8.4% |
Non-Operating Items | |||||
Interest Income | 359.0K | 240.0K | 0 | 0 | 21.0K |
Interest Expense | 1.1M | 2.0M | 1.0M | 11.3M | 7.2M |
Other Non-Operating Income | - | 3.0K | 1.5M | 2.4M | -27.0M |
Pre-tax Income | -10.2M | -7.9M | -6.4M | -10.2M | -21.2M |
Income Tax | -351.0K | -340.0K | 132.0K | 62.0K | -7.2M |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -9.9M | -7.5M | -6.5M | -10.3M | -14.0M |
Net Margin % | -8.0% | -6.6% | -6.0% | -8.3% | -9.0% |
Key Metrics | |||||
EBITDA | -2.2M | 825.0K | -1.2M | 5.7M | 20.1M |
EPS (Basic) | $-0.13 | $-0.10 | $-0.09 | $-0.17 | $-0.26 |
EPS (Diluted) | $-0.13 | $-0.10 | $-0.09 | $-0.17 | $-0.26 |
Basic Shares Outstanding | 77500000 | 76156000 | 72937000 | 60461000 | 54414000 |
Diluted Shares Outstanding | 77500000 | 76156000 | 72937000 | 60461000 | 54414000 |
Income Statement Trend
Performant Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 9.3M | 7.3M | 23.4M | 17.3M | 16.0M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 14.2M | 17.6M | 15.8M | 20.8M | 23.2M |
Inventory | - | - | - | - | - |
Other Current Assets | 4.0M | 3.7M | 3.7M | 3.1M | 3.8M |
Total Current Assets | 38.4M | 39.8M | 57.5M | 54.7M | 54.5M |
Non-Current Assets | |||||
Property, Plant & Equipment | 826.0K | 531.0K | 2.1M | 3.2M | 5.0M |
Goodwill | 94.7M | 94.7M | 94.7M | 94.7M | 95.4M |
Intangible Assets | - | - | - | - | 689.0K |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 1.2M | 2.3M | 1.0M | 963.0K | 1.1M |
Total Non-Current Assets | 63.4M | 59.2M | 61.3M | 67.3M | 71.7M |
Total Assets | 101.8M | 99.0M | 118.8M | 122.0M | 126.2M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 482.0K | 727.0K | 1.3M | 1.1M | 407.0K |
Short-term Debt | 383.0K | 250.0K | 2.2M | 2.4M | 62.3M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 2.6M | 3.0M | 3.4M | 4.9M | 4.9M |
Total Current Liabilities | 14.0M | 12.4M | 14.2M | 17.5M | 77.2M |
Non-Current Liabilities | |||||
Long-term Debt | 8.5M | 5.3M | 19.3M | 20.9M | 3.4M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 156.0K | 648.0K | 881.0K | 1.2M | 3.6M |
Total Non-Current Liabilities | 11.3M | 5.9M | 20.1M | 22.1M | 7.0M |
Total Liabilities | 25.3M | 18.3M | 34.3M | 39.6M | 84.2M |
Equity | |||||
Common Stock | 8.0K | 8.0K | 7.0K | 7.0K | 5.0K |
Retained Earnings | -75.2M | -65.3M | -57.8M | -51.2M | -41.0M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 76.5M | 80.7M | 84.5M | 82.4M | 42.0M |
Key Metrics | |||||
Total Debt | 8.8M | 5.5M | 21.5M | 23.2M | 65.7M |
Working Capital | 24.4M | 27.4M | 43.3M | 37.2M | -22.7M |
Balance Sheet Composition
Performant Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -9.9M | -7.5M | -6.5M | -10.3M | -14.0M |
Depreciation & Amortization | 6.9M | 6.7M | 5.7M | 7.0M | 7.0M |
Stock-Based Compensation | 5.9M | 3.9M | 3.0M | 2.6M | 2.6M |
Working Capital Changes | 2.7M | -1.3M | -1.6M | -4.1M | -5.3M |
Operating Cash Flow | 5.9M | 2.2M | 710.0K | -1.2M | -8.5M |
Investing Activities | |||||
Capital Expenditures | -7.0M | -4.1M | 1.3M | -3.4M | -3.8M |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -7.0M | -4.1M | 1.7M | -270.0K | -3.8M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 3.0M | 5.0M | 0 | 20.0M | 0 |
Debt Repayment | 0 | -19.5M | -500.0K | -60.9M | -3.4M |
Financing Cash Flow | 2.8M | -15.9M | -502.0K | 567.0K | -3.7M |
Free Cash Flow | -832.0K | -283.0K | -6.5M | -2.5M | 17.0M |
Net Change in Cash | 1.7M | -17.8M | 1.9M | -861.0K | -16.0M |
Cash Flow Trend
Performant Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-58.69
Forward P/E
60.24
Price to Book
7.33
Price to Sales
4.39
PEG Ratio
0.34
Profitability Ratios
Profit Margin
-0.64%
Operating Margin
6.98%
Return on Equity
-1.12%
Return on Assets
-0.03%
Financial Health
Current Ratio
2.64
Debt to Equity
11.04
Beta
0.41
Per Share Data
EPS (TTM)
$-0.01
Book Value per Share
$1.04
Revenue per Share
$1.76
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
phlt | 218.4M | -58.69 | 7.33 | -1.12% | -0.64% | 11.04 |
Veeva Systems | 44.1B | 55.52 | 6.66 | 13.70% | 27.29% | 1.29 |
Ge Healthcare | 39.5B | 15.11 | 3.47 | 25.80% | 11.22% | 107.67 |
Sophia Genetics SA | 226.4M | -3.61 | 3.05 | -74.09% | -105.32% | 83.21 |
LifeMD | 199.6M | -11.64 | 716.45 | 543.53% | -2.41% | 5,767.28 |
American Well | 122.2M | -0.49 | 0.39 | -37.62% | -46.16% | 2.17 |
Financial data is updated regularly. All figures are in the company's reporting currency.